Navigation Links
Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:10/25/2011

NEW YORK, Oct. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0332350/Epilepsy-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global epilepsy therapeutics market, identifying the key trends shaping and driving the global epilepsy market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global epilepsy sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates the global epilepsy therapeutics market to be worth $2.9 billion in 2010, and is forecast to register a slow growth with a Compound Annual Growth Rate (CAGR) of 3.5% annually to reach $3.8 billion by 2018. Generic erosion of the leading second generation antiepileptic drugs (AEDs) such as Keppra (levetiracetam), Lamictal (lamotrigine), Topamax (topiramate) and so on is the major factor for the slow growth of the epilepsy therapeutics market during the forecast period. The market is forecast to register a decline owing to competition from generics which is predicted to increase over the coming years. Increasing penetration and availability of generics is likely to act as a barrier for the future market players. The introduction and the patent expiry of the drugs such as Keppra, Lamictal, Topamax and so on across the seven major markets at different time periods has accounted for a CAGR of 5.3% during the period 2005-2010. The launch of new drugs such as Potiga (ezogabine)/Trobalt (retigabine), brivaracetam and Stedesa (eslicarbazepine acetate) (US) offering better efficacy and safety are expected to sustain a positive growth through 2018

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the epilepsy market. Its scope includes -

- Annualized global epilepsy market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under the therapy classes such as voltage gated sodium channel blocker. Gabaergic which include GABA enhancer, GABA-A receptor agonist and GABA aminotransferase inhibitor. Glutamate receptor includes AMPA receptor antagonist and NMDA antagonist. Voltage dependent calcium channel, neuronal potassium channel opener, high affinity to synaptic vesicle protein 2A (SV2A) and inhibitory activity at neuronal voltage-dependent sodium channels, caspase-1 Inhibitor, sigma 1 receptor agonist, CB1 receptors, GTPase dynamin Inhibitor.

- Analysis of the current and future competition in the global epilepsy market. Key market players covered are UCB, Pfizer, Supernus Pharma, Sunovion, GSK, Nobelpharma, Lundbeck and Eisai are the key players.

- An Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics coverage, including strategic competitor assessment, market characterization, unmet needs and the implications for the epilepsy therapeutics market.

- Analysis of key recent licensing and partnership agreements in the epilepsy therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.

- Develop business strategies by understanding the trends shaping and driving the global epilepsy market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global epilepsy market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global epilepsy market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 7

2 Epilepsy Therapeutics: Executive Summary 9

2.1 The Epilepsy Therapeutics Market is Forecast to Register Slow Growth Through 2018 9

2.2 Unmet Need Continues to Remain Unaddressed 10

2.3 Current Market Moderately Successful in Meeting Patients' Expectations 11

2.4 The Leading Participants of the Market are Likely to Maintain there Position Through 2018. 11

3 Epilepsy Therapeutics: Introduction 12

3.1 Epileptic Seizures Classification 12

3.1.1 Partial seizures 12

3.1.2 Generalized seizures 12

3.1.3 Unclassified seizures 13

3.1.4 Infantile spasms 13

3.2 Seizure Clusters 13

3.3 Epidemiology 13

3.3.1 Worldwide Prevalence 13

3.3.2 Incidence Rate 14

3.3.3 Co-morbidity 14

3.3.4 Quality of Life (QOL) 14

3.3.5 Economic Burden 15

3.4 Etiology 15

3.5 Signs and Symptoms 16

3.6 Causes 16

3.7 Diagnosis 16

3.7.1 Tests for Epilepsy 17

3.8 Treatment of Patient with Epilepsy 17

3.8.1 Antiepileptic Drug Monotherapy 17

3.8.2 Management of Drug-Resistant Epilepsy 18

3.9 Referral Pathway 19

3.10 GlobalData Pipeline Report Guidance 20

4 Epilepsy Therapeutics: Market Characterization 22

4.1 Overview 22

4.2 Epilepsy Therapeutics Market Size 22

4.3 Epilepsy Therapeutics Market Size (2005-2010) – Global 22

4.4 Epilepsy Therapeutics Market Forecast (2010-2018) – Global 23

4.5 Epilepsy Therapeutics Market Size (2005–2010) – The US 25

4.6 Epilepsy Therapeutics Market Forecast (2010-2018) – The US 26

4.7 Epilepsy Therapeutics Market Size (2005–2010) – France 27

4.8 Epilepsy Therapeutics Market Forecast (2010–2018) – France 28

4.9 Epilepsy Therapeutics Market Size (2005–2010) – Germany 29

4.10 Epilepsy Therapeutics Market Forecast (2010–2018) – Germany 30

4.11 Epilepsy Therapeutics Market Size (2005–2010) – Italy 31

4.12 Epilepsy Therapeutics Market Forecast (2010–2018) – Italy 32

4.13 Epilepsy Therapeutics Market Size (2005–2010) – Spain 33

4.14 Epilepsy Therapeutics Market Forecast (2010–2018) – Spain 34

4.15 Epilepsy Therapeutics Market Size (2005–2010) – The UK 35

4.16 Epilepsy Therapeutics Market Forecast (2010–2018) – The UK 36

4.17 Epilepsy Therapeutics Market Size (2005–2010) – Japan 37

4.18 Epilepsy Therapeutics Market Forecast (2010–2018) – Japan 38

4.19 Drivers and Barriers for the Epilepsy Therapeutics Market 39

4.19.1 Drivers for the Epilepsy Therapeutics Market 39

4.19.2 Barriers for the Epilepsy Therapeutics Market 39

4.20 Opportunity and Unmet Need 40

4.21 Key Takeaway 42

5 Epilepsy Therapeutics: Competitive Assessment 43

5.1 Overview 43

5.2 Strategic Competitor Assessment 43

5.3 Product Profiles for the Major Marketed Products in the Epilepsy Therapeutics Market 44

5.3.1 Keppra (levetiracetam) 44

5.3.2 Lamictal (lamotrigine) 47

5.3.3 Zebinix (eslicarbazepine acetate) 49

5.3.4 Lyrica (pregabalin) 49

5.3.5 Gabitril (tiagabine HCl) 51

5.3.6 Vimpat (lacosamide) 52

5.4 Key Takeaway 54

6 Epilepsy Therapeutics: Pipeline Assessment 55

6.1 Overview 55

6.2 Strategic Pipeline Assessment 55

6.3 Epilepsy Therapeutics Pipeline – Pipeline by Phases of Development 55

6.3.1 Epilepsy Therapeutics – Filed Pipeline 55

6.3.2 Epilepsy Therapeutics – Phase III Pipeline 56

6.3.3 Epilepsy Therapeutics – Phase II/III Pipeline 57

6.3.4 Epilepsy Therapeutics – Phase II Pipeline 57

6.3.5 Epilepsy Therapeutics – Phase I Pipeline 57

6.3.6 Epilepsy Therapeutics Market – Pre-clinical Pipeline 58

6.3.7 Epilepsy Therapeutics Market – Discovery Pipeline 59

6.3.8 Technology Trends Analytic Framework 59

6.4 Epilepsy Therapeutics Market – Pipeline by Mechanism of Action 61

6.5 Epilepsy Therapeutics – Promising Drugs under Clinical Development 62

6.6 Molecule Profile for Promising Drugs under Clinical Development 63

6.6.1 SPN-538 63

6.6.2 Trobalt/Potiga 63

6.6.3 Clobazam 64

6.6.4 Brivaracetam 65

6.6.5 NPC-06 66

6.7 Key Takeaway 66

7 Epilepsy Therapeutics: Clinical Trials Mapping 68

7.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 68

7.2 Clinical Trials by Phase 69

7.3 Clinical Trials by Trial Status 70

7.4 Prominent Sponsors 71

7.5 Top Companies Participating in Epilepsy Therapeutics Clinical Trials 73

8 Strategic Assessment 74

8.1 Key Events Impacting the Future Market 74

8.2 Epilepsy Therapeutics: Implications for Future Market Competition 75

9 Epilepsy Therapeutics: Future Players 77

9.1 Introduction 77

9.2 Company Profiles 78

9.2.1 UCB S.A. 78

9.2.2 Pfizer 79

9.2.3 Supernus Pharmaceuticals, Inc. 81

9.2.4 Sunovion Pharmaceuticals Inc. 83

9.2.5 GlaxoSmithKline plc 85

9.2.6 Nobelpharma Co., Ltd. 88

9.2.7 H Lundbeck A/S 89

9.2.8 Eisai Co., Ltd. 90

9.2.9 Kirin Holdings Company, Limited 93

9.2.10 Upsher-smith Laboratories, Inc. 95

10 Epilepsy Therapeutics: Licensing and Partnership Deals 97

11 Epilepsy Therapeutics: Appendix 125

11.1 Market Definitions 125

11.2 Abbreviations 125

11.3 Methodology 126

11.3.1 Coverage 126

11.3.2 Secondary Research 126

11.3.3 Forecasting 127

11.3.4 Primary Research 128

11.3.5 Expert Panel Validation 129

11.4 Contact Us 129

11.5 Disclaimer 129

11.6 Bibliography 131

List of Tables

Table 1: Prevalence of Epilepsy in Major Markets 13

Figure 5: AED Options By Seizure Type 18

Table 2: Epilepsy Therapeutics Market, Global, Revenue ($bn), 2005–2010 23

Table 3: Epilepsy Therapeutics Market, Global, Forecast ($bn), 2010–2018 24

Table 4: Epilepsy Therapeutics Market, The US, Revenue ($m), 2005–2010 25

Table 5: Epilepsy Therapeutics Market, The US, Forecasts ($m), 2010–2018 26

Table 6: Epilepsy Therapeutics Market, France, Revenue ($m), 2005–2010 27

Table 7: Epilepsy Therapeutics Market, France, Forecasts ($m), 2010–2018 28

Table 8: Epilepsy Therapeutics Market, Germany, Revenue ($m), 2005–2010 29

Table 9: Epilepsy Therapeutics Market, Germany, Forecasts ($m), 2010–2018 30

Table 10: Epilepsy Therapeutics Market, Italy, Revenue ($m), 2005–2010 31

Table 11: Epilepsy Therapeutics Market, Italy, Forecasts ($m), 2010–2018 32

Table 12: Epilepsy Therapeutics Market, Spain, Revenue ($m), 2005–2010 33

Table 13: Epilepsy Therapeutics Market, Spain, Forecasts ($m), 2010–2018 35

Table 14: Epilepsy Therapeutics Market, The UK, Revenue ($m), 2005–2010 36

Table 15: Epilepsy Therapeutics Market, The UK, Forecasts ($m), 2010–2018 37

Table 16: Epilepsy Therapeutics Market, Japan, Revenue ($m), 2005–2010 38

Table 17: Depression Therapeutics Market, Global, Forecast ($m), 2010–2018 39

Table 18: Incidence (%) Of Treatment-Emergent Adverse Events 46

Table 19: Seizure Response in Controlled, Add-On Epilepsy Studies 51

Table 20: Epilepsy Therapeutics, Regulatory Filed Pipeline, 2011 56

Table 21: Epilepsy Therapeutics, Phase III Pipeline, 2011 56

Table 22: Epilepsy Therapeutics, Phase II/III Pipeline, 2011 57

Table 23: Epilepsy Therapeutics, Phase II Pipeline, 2011 57

Table 24: Epilepsy Therapeutics, Phase I Pipeline, 2011 58

Table 25: Epilepsy Therapeutics, Pre-clinical Pipeline, 2011 58

Table 26: Epilepsy Therapeutics, Discovery Pipeline, 2011 59

Table 27: Epilepsy Therapeutics, Most Promising Drugs Under Clinical Development, 2011 63

Table 28: Epilepsy Therapeutics Market, Clinical Trials by Country, 2011 69

Table 29: Epilepsy Therapeutics, Clinical Trials by Phase, 2011 70

Table 30: Epilepsy Therapeutics, Clinical Trials by Status, 2011 71

Table 31: Epilepsy Therapeutics, Prominent Sponsors, 2011 72

Table 32: Epilepsy Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 73

Table 33: UCB, CNS Pipeline, 2011 78

Table 34: UCB, Epilepsy Pipeline, 2011 78

Table 35: Pfizer, CNS Pipeline, 2011 81

Table 36: Pfizer, Epilepsy Pipeline, 2011 81

Table 37: Supernus Pharmaceuticals, Inc., CNS Pipeline, 2011 83

Table 38: Supernus Pharmaceuticals, Inc., Epilepsy Pipeline, 2011 83

Table 39: Sunovion Pharmaceuticals Inc., CNS Pipeline, 2011 85

Table 40: Sunovion Pharmaceuticals Inc., Epilepsy Pipeline, 2011 85

Table 41: GSK, CNS Pipeline, 2011 88

Table 42: GSK, Epilepsy Pipeline, 2011 88

Table 43: Nobelpharma Co., Ltd. CNS Pipeline, 2011 89

Table 44: Nobelpharma Co., Ltd. CNS Pipeline, 2011 89

Table 45: H Lundbeck A/S, CNS Pipeline, 2011 90

Table 46: H Lundbeck A/S, Epilepsy Pipeline, 2011 90

Table 47: Eisai Co., Ltd., CNS Pipeline, 2011 93

Table 48: Eisai Co., Ltd., Epilepsy Pipeline, 2011 93

Table 49: Kyowa Hakko Kirin Co.,Ltd,CNS Pipeline, 2011 95

Table 50: Kyowa Hakko Kirin Co.,Ltd, Epilepsy Pipeline, 2011 95

Table 51: Upsher-smith Laboratories, Inc, CNS Pipeline, 2011 96

Table 52: Upsher-smith Laboratories, Inc, CNS Pipeline, 2011 96

Table 53: Epilepsy Therapeutics, Global, Deals, 2009-2011 97

List of Figures

Figure 1: Epilepsy Therapeutics Market, Global, Market Revenue ($bn), 2005–2018 9

Figure 2: Opportunity and Unmet Need in the Epilepsy Therapeutics Market, 2010 10

Figure 3: Health Related Quality of Life 14

Figure 4: Etiology of Epilepsy in Elderly People 15

Figure 6: Epilepsy Referral Pathway 19

Figure 7: Epilepsy Therapeutics Market, Global, Revenue ($bn), 2005–2010 23

Figure 8: Epilepsy Therapeutics Market, Global, Forecast ($bn), 2010–2018 24

Figure 9: Epilepsy Therapeutics Market, The US, Revenue ($m), 2005–2010 25

Figure 10: Epilepsy Therapeutics Market, The US, Forecasts ($m), 2010–2018 26

Figure 11: Epilepsy Therapeutics Market, France, Revenue ($m), 2005–2010 27

Figure 12: Epilepsy Therapeutics Market, France, Forecasts ($m), 2010–2018 28

Figure 13: Epilepsy Therapeutics Market, Germany, Revenue ($m), 2005–2010 29

Figure 14: Epilepsy Therapeutics Market, Germany, Forecasts ($m), 2010–2018 30

Figure 15: Epilepsy Therapeutics Market, Italy, Revenue ($m), 2005–2010 31

Figure 16: Epilepsy Therapeutics Market, Italy, Forecasts ($m), 2010–2018 32

Figure 17: Epilepsy Therapeutics Market, Spain, Revenue ($m), 2005–2010 33

Figure 18: Epilepsy Therapeutics Market, Spain, Forecasts ($m), 2010–2018 34

Figure 19: Epilepsy Therapeutics Market, The UK, Revenue ($m), 2005–2010 35

Figure 20: Epilepsy Therapeutics Market, The UK, Forecasts ($m), 2010–2018 36

Figure 21: Epilepsy Therapeutics Market, Japan, Revenue ($m), 2005–2010 37

Figure 22: Epilepsy Therapeutics Market, Japan, Forecasts ($m), 2010–2018 38

Figure 23: Opportunity and Unmet Need in the Epilepsy Therapeutics Market, 2010 41

Figure 24: Epilepsy Therapeutics, Strategic Competitor Assessment, 2011 43

Figure 25: Epilepsy Therapeutics, Pipeline by Phase of Development, 2011 55

Figure 26: Epilepsy Therapeutics, Technology Trends Analytics Framework, 2011 60

Figure 27: Epilepsy Therapeutics, Technology Trends Analytics Framework – Description, 2011 61

Figure 28: Epilepsy Therapeutics, Pipeline by Mechanism of Action, 2011 62

Figure 29: Epilepsy Therapeutics Market, Clinical Trials by Country, 2011 68

Figure 30: Epilepsy Therapeutics, Clinical Trials by Phase, 2011 69

Figure 31: Epilepsy Therapeutics, Clinical Trials by Status, 2011 70

Figure 32: Epilepsy Therapeutics Market, Overall Sponsors, 2011 71

Figure 33: Epilepsy Therapeutics, Prominent Sponsors, 2011 72

Figure 32: Epilepsy Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 73

Figure 34: Epilepsy Therapeutics Market, Drivers and Restraints, 2011 74

Figure 35: Implications for Future Market Competition in the Epilepsy Market, 2011 75

Figure 36: Epilepsy Therapeutics Market, Pipeline by Company, 2011 77UCB S.A.

Pfizer

Supernus Pharmaceuticals, Inc.

Sunovion Pharmaceuticals Inc.

GlaxoSmithKline plc

Nobelpharma Co., Ltd.

H Lundbeck A/S

Eisai Co., Ltd.

Kirin Holdings Company, Limited

Upsher-smith Laboratories, Inc.

To order this report:

Pathology Industry: Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Pathology Business News

More  Industry Analysis and Insights

__________________________

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Epilepsy Therapy Project Announces "Shark Tank" Competition to Identify the Most Innovative, New Products for People with Epilepsy
2. Editor-in-Chief of Elseviers Epilepsy & Behavior presented with Ambassador for Epilepsy Award
3. NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy
4. NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial
5. Topiramate Exposure and Birth Defect Data to be Presented at the 29th International Epilepsy Congress
6. Texas Childrens Hospital Pioneers Use of MRI-guided Laser Surgery for Revolutionary New Epilepsy Treatment
7. Upsher-Smith Laboratories Begins Phase III Study of Intranasal Midazolam for Rescue Treatment of Seizure Clusters in Epilepsy Patients
8. Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
9. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
10. Biopharma Company UCB Unveils 40 Deserving 2010 Family Epilepsy Scholarship Recipients
11. The Epilepsy Drug Market Will Remain Relatively Flat Through 2019 as Generic Erosion, Especially Within the Second-Generation Antiepileptic Drug Class, is Offset by the Launch of New Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...  EIP Pharma, LLC ( www.eippharma.com ) today ... (previously code named VX-745), with the results of ... demonstrated significant Alzheimer,s disease relevant pharmacological activity.  The ... 303 (6-week treatment) are the subject of presentations ... scientific conference in San Diego, CA ...
(Date:12/8/2016)... Dignitana, a world leader in medical scalp-cooling ... creator of the award-winning, patented Boa® system, to produce ... DigniCap® scalp cooling system. DigniCap® was cleared by the ... is the first medical scalp cooling device to receive ... features a patented tight-fitting silicone cooling cap that is ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... dedicated to improving cancer patient care from diagnosis ... the company,s recently completed Phase 1b study in ... at the San Antonio Breast Cancer Symposium. ... Cancer Center at UC San Diego Health, delivered ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... Healthcare is in flux. The GOP wants ... mass media launching of story movements to highlight what's most unfair about healthcare. ... such a movement can generate the network power to improve healthcare policies in ...
(Date:12/8/2016)... ... 08, 2016 , ... Dickinson Insurance and Financial Services, an ... Rock, has initiated a charity drive to provide support and funding to the ... Hunger, Arkansas ranks first in senior hunger statewide, third in child hunger, and ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... offices headquartered in Jefferson County, is announcing the launch of a charity drive ... The number of homeless women and children in Birmingham has grown steadily since ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coppin Insurance Agency, an insurance and ... and around the Cape Coral area, is embarking on a charity drive with the ... Florida. , The Harry Chapin Food Bank of Southwest Florida works to provide fresh ...
(Date:12/8/2016)... Fort Payne, AL (PRWEB) , ... December 08, ... ... enterprise offering insurance and financial consulting services to residential and commercial clients in ... raise awareness and support for Nobis Works. , Since 1977, Nobis Works has ...
Breaking Medicine News(10 mins):